Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Vaxart Publishes Complete Data From Phase 2b Challenge Study Of First-Generation Oral Pill Norovirus Vaccine Candidate In Science Translational Medicine

Author: Benzinga Newsdesk | May 14, 2025 04:17pm

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding

Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart's second-generation norovirus vaccine candidate, which is being evaluated in a Phase 1 clinical trial

Posted In: VXRT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist